LexaGene is developing an on-site, automated genetic analyzer for rapid pathogen detection for human clinical diagnostics, veterinary diagnostics, food safety and more.
Our breakthrough technology will transform how pathogens are detected and deliver results in about an hour.
28 May 2020 – LexaGene places a pre-Commercial instrument for COVID-19 testing at the Dartmouth-Hitchcock Medical Center laboratory.
Innovation in the Making
Imagine a new way of testing on site for multiple pathogens that uses customized genetic screening, doesn’t require a skilled technician,
and returns results in just one hour. See what’s new with LexaGene and how we are changing the future of pathogen detection.
LexaGene on-site analyzer for coronavirus
LexaGene has developed a rapid, on-site diagnostic analyzer to be used at point-of-need at airports and hospitals for 1-hour results or less. Read news release.
LexaGene Company Presentation
We are commercializing the first ‘open-access’ instrument for pathogen detection, allowing users an on-site instrument to target any gene sequence of interest and return results in about an hour.
Forbes feature on LexaGene
Forbes profile on LexaGene’s technology: ‘It’s hard to imagine a startup better positioned to respond to the coronavirus pandemic than Beverly, Massachusetts-based LexaGene.’